

David E Kandzari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2810879/publications.pdf>

Version: 2024-02-01

152
papers

13,956
citations

31902

53
h-index

20307

116
g-index

154
all docs

154
docs citations

154
times ranked

7927
citing authors

#	ARTICLE	IF	CITATIONS
1	Procedural Effectiveness With a Focused Force Scoring Angioplasty Catheter: Procedural and Clinical Outcomes From the Scoreflex NC Trial. <i>Cardiovascular Revascularization Medicine</i> , 2022, 35, 85-90.	0.3	2
2	Clinical outcomes according to lesion complexity in high bleeding risk patients treated with 1-month dual antiplatelet therapy following <sc>PCI</sc>: Analysis from the <sc>Onyx ONE</sc> clear study. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 583-592.	0.7	3
3	Safety and efficacy of dedicated guidewire, microcatheter, and guide catheter extension technologies for chronic total coronary occlusion revascularization: Primary results of the Teleflex Chronic Total Occlusion Study. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 263-270.	0.7	2
4	Complex vs. non-complex percutaneous coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials. <i>Clinical Research in Cardiology</i> , 2022, 111, 795-805.	1.5	8
5	Randomized evaluation of vessel preparation with orbital atherectomy prior to drug-eluting stent implantation in severely calcified coronary artery lesions: Design and rationale of the ECLIPSE trial. <i>American Heart Journal</i> , 2022, 249, 1-11.	1.2	13
6	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. <i>Circulation</i> , 2022, 145, 847-863.	1.6	28
7	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL) Tj ETQq1 1 0,784314 rgBT /Ovrd	6.3	114
8	Clinical Experience of the PK Papyrus Covered Stent in Patients With Coronary Artery Perforations: Results From a Multi-Center Humanitarian Device Exemption Survey. <i>Cardiovascular Revascularization Medicine</i> , 2022, 43, 97-101.	0.3	7
9	Timing of Stent Thrombosis After 1-Month Discontinuation of Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1963-1965.	1.2	0
10	Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial. <i>Hypertension</i> , 2022, 79, 1506-1514.	1.3	10
11	Impact of lesion preparation strategies on outcomes of left main <sc>PCI</sc>: The <sc>EXCEL</sc> trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 24-32.	0.7	7
12	Antithrombotic regimens for percutaneous coronary intervention of the left main coronary artery: The EXCEL trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 766-773.	0.7	4
13	Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 725-731.	1.5	17
14	Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrineâ„¢ Infusion Catheter. <i>Cardiovascular Revascularization Medicine</i> , 2021, 24, 77-86.	0.3	4
15	Outpatient Versus Inpatient Percutaneous Coronary Intervention in Patients With Left Main Disease (from the EXCEL Trial). <i>American Journal of Cardiology</i> , 2021, 143, 21-28.	0.7	0
16	Prioritised endpoints for device-based hypertension trials: the win ratio methodology. <i>EuroIntervention</i> , 2021, 16, e1496-e1502.	1.4	12
17	Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: A meta-analysis of individual patient data from 5 randomized trials. <i>American Heart Journal</i> , 2021, 235, 140-148.	1.2	14
18	Impact of Coronary Calcification on Clinical Outcomes After Implantation of Newer-Generation Drug-Eluting Stents. <i>Journal of the American Heart Association</i> , 2021, 10, e019815.	1.6	14

#	ARTICLE	IF	CITATIONS
19	Does study subject diversity influence cardiology research site performance?: Insights from 2 U.S. National Coronary Stent Registries. <i>American Heart Journal</i> , 2021, 236, 37-48.	1.2	2
20	Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2909-2919.	1.2	63
21	Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by <scp>SCAI</scp> and <scp>NKF</scp>. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 416-426.	0.7	21
22	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1028-1038.	1.2	27
23	A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions. <i>Contemporary Clinical Trials Communications</i> , 2021, 23, 100818.	0.5	3
24	Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications. <i>American Heart Journal</i> , 2021, 239, 90-99.	1.2	16
25	Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010075.	1.4	8
26	Blood pressure lowering with alcohol-mediated renal denervation using the Peregrine infusion Catheter is independent of injection site location. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E832-E838.	0.7	0
27	Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension. <i>Journal of Hypertension</i> , 2021, 39, 162-168.	0.3	29
28	Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. <i>Circulation</i> , 2021, 143, 479-500.	1.6	132
29	Mirror, Mirror on the Wall: Who is the Fairest Meta-Analysis of All?. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2625-2628.	1.1	0
30	Break on through to the other side: crossover in renal denervation trials. <i>EuroIntervention</i> , 2021, 17, e961-e962.	1.4	0
31	Catheter-Based Renal Denervation Therapy: Evolution of Evidence and Future Directions. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e011130.	1.4	2
32	Procedural, clinical, and health status outcomes in chronic total coronary occlusion revascularization: Results from the PERSPECTIVE study. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 567-576.	0.7	5
33	Cost and Mortality Implications of Lower Event Rates After Implantation of an Ultrathin-Strut Coronary Stent Compared With a Thin-Strut Stent Over Four Years. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 835-842.	0.3	2
34	Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 86-93.	1.1	3
35	One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009565.	1.4	49
36	Individual patient data analysis of the BIOFLOW study program comparing safety and efficacy of a bioresorbable polymer sirolimus eluting stent to a durable polymer everolimus eluting stent. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 98, 848-856.	0.7	3

#	ARTICLE	IF	CITATIONS
37	Chronic Total Occlusions. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009724.	1.4	3
38	Comparison of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents and Thin, Durable-Polymer Everolimus-Eluting Stents in Calcified or Small Vessel Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009189.	1.4	11
39	Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1343-1353.	1.1	68
40	Management of Percutaneous Coronary Intervention Complications. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008962.	1.4	46
41	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL) Tj ETQq1 1 0.784314 rgBT /Over 1444-1451.	6.3	351
42	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. <i>Clinical Research in Cardiology</i> , 2020, 109, 289-302.	1.5	28
43	Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. <i>New England Journal of Medicine</i> , 2020, 382, 1208-1218.	13.9	207
44	Coronary Occlusion During TAVR. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 762-764.	1.1	0
45	Confounding Factors in Renal Denervation Trials. <i>Hypertension</i> , 2020, 76, 1410-1417.	1.3	33
46	Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007734.	1.4	6
47	Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2019, 124, 1020-1026.	0.7	11
48	Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 420-433.	1.6	263
49	Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy. <i>Hypertension</i> , 2019, 74, 244-249.	1.3	17
50	Renal Denervation for Treating Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1095-1105.	1.1	61
51	Late-term safety and effectiveness of everolimus-eluting stents in chronic total coronary occlusion revascularization: Final 4-year results from the evaluation of the XIENCE coronary stent, performance, and technique in chronic total occlusions (EXPERT) Tj ETQq1 1 0.784314 rgBT /Over	0.7	5
52	Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. <i>New England Journal of Medicine</i> , 2019, 381, 1820-1830.	13.9	523
53	Small-vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus-eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post-Approval studies. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 82-90.	0.7	10
54	Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1-month of dual antiplatelet therapy. <i>American Heart Journal</i> , 2019, 214, 134-141.	1.2	31

#	ARTICLE	IF	CITATIONS
55	Renal denervation for hypertension: what is needed, and what is next. <i>European Heart Journal</i> , 2019, 40, 3483-3485.	1.0	3
56	Impact of Race and Ethnicity on the Clinical and Angiographic Characteristics, Social Determinants of Health, and 1-Year Outcomes After Everolimus-Eluting Coronary Stent Procedures in Women. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e006918.	1.4	12
57	PK Papyrus covered stent: Device description and early experience for the treatment of coronary artery perforations. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 564-568.	0.7	25
58	Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the EXCEL trial. <i>European Heart Journal</i> , 2019, 40, 1930-1941.	1.0	65
59	Final 5-Year Results in Unselected Patients Implanted With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent (from the PROMUS Element Plus US Post-Approval Study). <i>American Journal of Cardiology</i> , 2019, 123, 1765-1771.	0.7	3
60	Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. <i>European Heart Journal</i> , 2019, 40, 743-751.	1.0	70
61	The Day After a Primary Endpoint. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 470-472.	1.1	0
62	Bioresorbable polymer drug-eluting stents – Authors' reply. <i>Lancet, The</i> , 2018, 391, 936-937.	6.3	0
63	Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3287-3297.	1.2	73
64	Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2467-2476.	1.1	38
65	Outcomes Among Patients Undergoing Distal Left Main Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007007.	1.4	45
66	Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007331.	1.4	23
67	Safety and efficacy of dedicated guidewire and microcatheter technology for chronic total coronary occlusion revascularization. <i>Coronary Artery Disease</i> , 2018, 29, 618-623.	0.3	10
68	Efficacy and Safety of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents With a Single Month of Dual Antiplatelet Therapy. <i>JAMA Cardiology</i> , 2018, 3, 1050.	3.0	26
69	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. <i>Lancet, The</i> , 2018, 391, 2346-2355.	6.3	597
70	A prospective randomised trial comparing the novel ridaforolimus-eluting BioNIR stent to the zotarolimus-eluting Resolute stent: six-month angiographic and one-year clinical results of the NIREUS trial. <i>EuroIntervention</i> , 2018, 14, 86-93.	1.4	11
71	Will SPYRAL HTN-ON MED change my practice? SPYRAL HTN-ON MED: a prospective, randomised, sham-controlled trial on renal denervation in the presence of antihypertensive medications. <i>EuroIntervention</i> , 2018, 14, e598-e602.	1.4	3
72	Balloon –Valvuloplasty–for Mechanical–Valve Dysfunction. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, e47-e49.	1.1	1

#	ARTICLE	IF	CITATIONS
73	Quality-of-Life After Everolimus-Eluting Stents or Bypass Surgery for Left-Main Disease. Journal of the American College of Cardiology, 2017, 70, 3113-3122.	1.2	69
74	Outcomes in Women and Minorities Compared With White Men 1 Year After Everolimus-Eluting Stent Implantation. JAMA Cardiology, 2017, 2, 1303.	3.0	46
75	Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet, The, 2017, 390, 1843-1852.	6.3	214
76	Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease. Circulation, 2017, 136, 1304-1314.	1.6	43
77	Left Main Disease. JACC: Cardiovascular Interventions, 2017, 10, 2411-2413.	1.1	0
78	Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach. American Heart Journal, 2017, 193, 35-45.	1.2	13
79	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet, The, 2017, 390, 2160-2170.	6.3	597
80	<scp>Frequency</scp> and Implications of Ischemia Prior to Ventricular Tachyarrhythmia in Patients Treated With a Wearable Cardioverter Defibrillator Following Myocardial Infarction. Clinical Cardiology, 2016, 39, 399-405.	0.7	6
81	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 674-684.	1.1	51
82	Renal Denervation: Past, Present, and Future. Cardiovascular Innovations and Applications, 2016, 1, .	0.1	0
83	Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPPLICITY HTN-3 and the Global SYMPPLICITY Registry. European Heart Journal, 2016, 38, ehw325.	1.0	104
84	Motherâ€œDaughterâ€œGranddaughter Double GuideLiner Technique for Delivering Stents Past Multiple Extreme Angulations. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	12
85	Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertensionâ€œâ€œ Insights From the SYMPPLICITY HTN-3 Trial â€œ. Circulation Journal, 2016, 80, 1404-1412.	0.7	64
86	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. New England Journal of Medicine, 2016, 375, 2223-2235.	13.9	843
87	Outcomes With the Use of the Retrograde Approach for Coronary Chronic Total Occlusion Interventions in a Contemporary Multicenter US Registry. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	94
88	Influence of Total Coronary Occlusion on Clinical Outcomes (from the Bypass Angioplasty) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 142 Td	0.7	19
89	One-Year Outcomes in â€œReal-Worldâ€œPatients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent (from the PROMUS Element Plus US Post-Approval Study [PE-Plus PAS]). American Journal of Cardiology, 2016, 117, 539-545.	0.7	15
90	Canâ€œt Bare It Any Longer. JACC: Cardiovascular Interventions, 2016, 9, 437-439.	1.1	2

#	ARTICLE	IF	CITATIONS
91	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e002995.	1.4	12
92	Development and Validation of a Novel Scoring System for Predicting Technical Success of Chronic Total Occlusion Percutaneous Coronary Interventions. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1-9.	1.1	276
93	The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. <i>American Heart Journal</i> , 2016, 171, 82-91.	1.2	132
94	Impact of Lesion Placement on Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1766-1775.	1.2	168
95	Renal Denervation for the Treatment of Hypertension: Making a New Start, Getting It Right. <i>Clinical Cardiology</i> , 2015, 38, 447-454.	0.7	9
96	Treatment of the chronic total occlusion: A call to action for the interventional community. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 771-778.	0.7	37
97	Renal denervation for the treatment of hypertension: Making a new start, getting it right. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 855-863.	0.7	3
98	Renal denervation therapy for hypertension: pathways for moving development forward. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 341-350.	2.3	36
99	Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 761-769.	1.1	48
100	Renal Denervation for the Treatment of Hypertension: Making a New Start, Getting It Right. <i>Journal of Clinical Hypertension</i> , 2015, 17, 743-750.	1.0	16
101	Stent Selection and Antiplatelet Therapy Duration. <i>Journal of the American College of Cardiology</i> , 2015, 65, 816-819.	1.2	3
102	Transradial approach for coronary chronic total occlusion interventions: Insights from a contemporary multicenter registry. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 1123-1129.	0.7	71
103	Application and outcomes of a hybrid approach to chronic total occlusion percutaneous coronary intervention in a contemporary multicenter US registry. <i>International Journal of Cardiology</i> , 2015, 198, 222-228.	0.8	137
104	Antiplatelet Therapy Duration Following Bare Metal or Drug-Eluting Coronary Stents. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1113.	3.8	82
105	12-Month Blood Pressure Results of Catheter-Based Renal Artery Denervation for Resistant Hypertension. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1314-1321.	1.2	103
106	An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPPLICITY HTN-3 trial. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 769-779.	2.3	36
107	Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1552-1562.	1.1	51
108	Clinical Utility of the Japan Chronic Total Occlusion Score in Coronary Chronic Total Occlusion Interventions. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002171.	1.4	93

#	ARTICLE	IF	CITATIONS
109	Predictors of blood pressure response in the SYMPPLICITY HTN-3 trial. <i>European Heart Journal</i> , 2015, 36, 219-227.	1.0	458
110	Percutaneous Intervention of Circumflex Chronic Total Occlusions Is Associated With Worse Procedural Outcomes: Insights From a Multicentre US Registry. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1588-1594.	0.8	44
111	Unintentional overestimation of an expected antihypertensive effect in drug and device trials: Mechanisms and solutions. <i>International Journal of Cardiology</i> , 2014, 172, 29-35.	0.8	31
112	Application of the "Hybrid Approach" to Chronic Total Occlusions in Patients With Previous Coronary Artery Bypass Graft Surgery (from a Contemporary Multicenter US Registry). <i>American Journal of Cardiology</i> , 2014, 113, 1990-1994.	0.7	75
113	First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31,379 patients. <i>Open Heart</i> , 2014, 1, e000064.	0.9	88
114	Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. <i>European Heart Journal</i> , 2014, 35, 1147-1158.	1.0	152
115	The impact of residual coronary lesions on clinical outcomes after percutaneous coronary intervention: Residual SYNTAX score after percutaneous coronary intervention in patients from the Efficacy of Xience/Promus versus Cypher in rEducing Late Loss after stENTing (EXCELLENT) registry. <i>American Heart Journal</i> , 2014, 167, 384-392.e5.	1.2	34
116	A Controlled Trial of Renal Denervation for Resistant Hypertension. <i>New England Journal of Medicine</i> , 2014, 370, 1393-1401.	13.9	1,848
117	Impact of Renal Denervation on 24-Hour Ambulatory Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1071-1078.	1.2	164
118	Stents: Safety and Efficacy. , 2014, , 115-141.		1
119	The efficacy and safety of the "hybrid" approach to coronary chronic total occlusions: insights from a contemporary multicenter US registry and comparison with prior studies. <i>Journal of Invasive Cardiology</i> , 2014, 26, 427-32.	0.4	66
120	Final 5-Year Outcomes From the Endeavor Zotarolimus-Eluting Stent Clinical Trial Program. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 504-512.	1.1	55
121	Ready for a Marathon, Not a Sprint. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2131-2133.	1.2	7
122	First-in-Human Evaluation of a Bioabsorbable Polymer-Coated Sirolimus-Eluting Stent. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1026-1034.	1.1	32
123	Not All Subintimal Chronic Total Occlusion Revascularization Is Alike. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2570.	1.2	6
124	The "Final" 5-Year Follow-Up From the ENDEAVOR IV Trial Comparing a Zotarolimus-Eluting Stent With a Paclitaxel-Eluting Stent. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 325-333.	1.1	72
125	Impact of prior coronary artery bypass graft surgery on chronic total occlusion revascularisation: insights from a multicentre US registry. <i>Heart</i> , 2013, 99, 1515-1518.	1.2	80
126	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. <i>BMJ</i> , The, 2013, 347, f6530-f6530.	3.0	194

#	ARTICLE	IF	CITATIONS
127	Long-term efficacy and safety of zotarolimus-eluting stent in patients with diabetes mellitus: Pooled 5-year results from the ENDEAVOR III and IV trials. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, 1031-1038.	0.7	11
128	Procedural Effectiveness of a Novel 1.20-mm Diameter Angioplasty Catheter: Clinical and Angiographic Outcomes. <i>Journal of Interventional Cardiology</i> , 2013, 26, 131-136.	0.5	1
129	Development of a high-volume, multiple-operator program for percutaneous chronic total coronary occlusion revascularization: procedural, clinical, and cost-utilization outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, 1-8.	0.7	89
130	Catheter-based Renal Sympathetic Denervation – Long-term Symplicity, Renal Denervation Clinical Evidence, New Data and Future Perspectives. <i>Interventional Cardiology Review</i> , 2013, 8, 118.	0.7	6
131	A Percutaneous Treatment Algorithm for Crossing Coronary Chronic Total Occlusions. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 367-379.	1.1	519
132	Retrograde Coronary Chronic Total Occlusion Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1273-1279.	1.1	137
133	Percutaneous coronary intervention of unprotected left main coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 812-822.	0.7	7
134	Catheter-Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPPLICITY HTN-3 Trial. <i>Clinical Cardiology</i> , 2012, 35, 528-535.	0.7	278
135	Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomised controlled clinical trials. <i>EuroIntervention</i> , 2012, 8, 187-195.	1.4	35
136	Dual Antiplatelet Therapy Duration and Clinical Outcomes Following Treatment With Zotarolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1119-1128.	1.1	37
137	Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 543-550.	1.1	97
138	Revascularization for Unprotected Left Main Coronary Artery Disease: An Evolution in Clinical Decision Making. <i>Current Cardiology Reports</i> , 2011, 13, 424-431.	1.3	2
139	Clinical outcomes following predilation with a novel 1.25-mm diameter angioplasty catheter. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 510-514.	0.7	5
140	Improved Late Clinical Safety With Zotarolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in Patients With De Novo Coronary Lesions. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1043-1050.	1.1	96
141	A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions. <i>Journal of the American College of Cardiology</i> , 2010, 55, 543-554.	1.2	217
142	Clinical and Angiographic Outcomes With Sirolimus-Eluting Stents in Total Coronary Occlusions. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 97-106.	1.1	73
143	Import and Export of Interventional Technique. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 843-845.	1.1	3
144	Identifying the –Optimal–Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1279-1285.	1.1	34

#	ARTICLE	IF	CITATIONS
145	Late Safety, Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions. JACC: Cardiovascular Interventions, 2009, 2, 1208-1218.	1.1	57
146	Revascularization for Unprotected Left Main Disease. Journal of the American College of Cardiology, 2009, 54, 1576-1588.	1.2	49
147	Angiographic Surrogate End Points in Drug-Eluting Stent Trials. Journal of the American College of Cardiology, 2008, 51, 23-32.	1.2	153
148	Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation. JAMA - Journal of the American Medical Association, 2007, 297, 159.	3.8	778
149	Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients With Native Coronary Artery Disease. Journal of the American College of Cardiology, 2006, 48, 2440-2447.	1.2	342
150	Percutaneous recanalization of chronically occluded coronary arteries: Procedural techniques, devices, and results. Catheterization and Cardiovascular Interventions, 2005, 66, 217-236.	0.7	119
151	Percutaneous Recanalization of Chronically Occluded Coronary Arteries. Circulation, 2005, 112, 2364-2372.	1.6	490
152	Advanced coronary artery disease: Appropriate end points for trials of novel therapies. American Heart Journal, 2001, 142, 843-851.	1.2	29